Stocktoria
Axsome Therapeutics, Inc. AXSM
Axsome Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — | — | — | — | — | — |
| R&D expense | $183.3M | $187.1M | $97.9M | $57.9M | $58.1M | $70.2M | $53.6M | $23.5M | $20.0M | $21.2M |
| SG&A expense | $570.6M | $411.4M | $323.1M | $159.3M | $66.6M | $28.9M | — | — | — | — |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M | -$99.1M | -$67.2M | -$32.8M | -$27.2M | -$27.5M |
| Interest expense | -$15.9M | -$21.6M | -$20.0M | -$9.7M | — | — | — | — | — | — |
| Income tax | -$530,000 | $85,000 | $960,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M | -$102.9M | -$68.3M | -$31.0M | -$28.9M | -$27.2M |
| EPS (diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | — | — | — | — |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M | -$78.5M | -$46.4M | -$30.1M | -$26.5M | -$21.3M |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M | -$78.5M | -$46.4M | -$30.1M | -$26.5M | -$21.4M |
| Cash & equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M | $183.9M | $220.0M | — | — | — |
| Inventory | $27.9M | $15.7M | $15.1M | $4.3M | — | — | — | — | — | — |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M | $186.1M | $220.5M | $15.4M | $35.6M | $38.2M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M | $72.3M | $41.8M | $14.4M | $18.8M | $16.6M |
| Shareholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M | $113.8M | $178.7M | $937,921 | $16.7M | $21.6M |
Growth · year-over-year · Revenue CAGR 133.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +65.5% | +42.5% | +440.8% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.